- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02510235
Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops in Subjects With Mod. Dry Eye
A Randomized, Double-masked, Controlled, Non-inferiority Study to Evaluate Tolerability, Safety and Efficacy of Lubricin Eye Drops vs Sodium Hyaluronate Eye Drops Given 4 Times a Day for 4 Weeks & 1 Week Follow-up in Subjects With Dry Eye
Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.
Lubricin is a mucin-like glycoprotein originally discovered in synovial fluid, as a secreted product of cells that line the joint tissues, which is present at the surface of articular cartilage and it has been investigated on its roles at the ocular surface, in normal and pathologic conditions such as dry eye.
The objective of the study is to assess the tolerability, safety and efficacy of Lubricin eye drops solution administered over 4 weeks versus sodium hyaluronate (Na-HY) eye drops solution in subjects with moderate dry eye.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dry eye, or keratoconjunctivitis sicca, is a chronic inflammatory condition of the ocular surface that may cause severe symptoms and visual impairment. The 2007 international dry eye workshop (DEWS) defined the disease as follows: "Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface".
Lubricin is a mucin-like glycoprotein originally discovered in synovial fluid, as a secreted product of cells that line the joint tissues, which is present at the surface of articular cartilage.
In vitro studies have shown that lubricin in saline buffer acts as a lubricant between various surfaces, as well as in synovial fluid, providing evidence that lubricin is a principal lubricating protein in joints. Besides the lubricating property, lubricin has been shown to exert anti-adhesive action, strain energy dissipation, and a protective effect on underlying cells.
Lubricin has been investigated on its roles at the ocular surface, in normal and pathologic conditions such as dry eye. In fact, Lubricin is a natural human protein with most potent lubricant and anti-adhesive properties present on the ocular surface and on meibonian gland. The presence of this protein at the ocular surface was first described by the team of Sullivan D.
Based on the available preclinical lubricin studies may be an important barrier to the development of corneal and conjunctival epitheliopathies in dry eyes and its use as a novel lubricating and anti-adhesive eye drop is under investigation in this clinical investigation. This clinical investigation has been designed to demonstrate that a Lubricin 150 µg/ml eye drop formulation is non-inferior to the currently most-widely used ocular surface lubricant sodium hyaluronate 0.13% in improving signs and symptoms in patients with moderate dry eye.
Up to now, there are no known anticipated adverse events associated with the use of lubricin, anyway the occurrence of side effects cannot be excluded.
It must be considered that topical treatment with lubricin or hyaluronic acid could cause local irritation or allergic reactions. There are no known contraindications to the use of lubricin or hyaluronic acid eye drops. All examinations and assessments that will be carried out during this study are non-invasive, are commonly used in the management of subjects with dry eye and pose no risk to the subjects. There are no known contraindications to the use of lubricin or hyaluronic acid eye drops. No data are available about the embryo and fetal toxicity, therefore the experimental treatment will not be allowed to pregnant women or nursing mothers and women of childbearing potential not using appropriate birth control methods.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Catania, Italy, 95123
- Azienda OspedalieroUniversitaria "Policlinico Vittorio Emanuele" Presidio Ospedaliero, Gaspare Rodolico Clinica Oculistica
-
Messina, Italy, 98125
- Centro Eccellenza Regionale Malattie della Superficie Oculare - Università di Messina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be checked at the screening visit (V1) from day -14 to day -8 days before run-in period and confirmed at baseline visit (V2):
- Subjects 18 years of age or older.
- Subjects with moderate dry eye characterized by tear film osmolarity > 312 mOsm
- Subjects with both VAS for frequency and severity of symptoms, SANDE items, at screening & baseline > 25 mm (SANDE overall score > 25 mm).
- Subjects with moderate dry eye characterized by at least one eye with signs and symptoms of moderate dry eye (grade 2 or 3 of the 2007 DEWS report)
- Subjects diagnosed with dry eye from at least 6 months (current use or recommended use of artificial tears/lubricants for the treatment of Dry Eye)
- Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment.
- The Informed Consent by approved Ethics Committees should be signed by the subject before any study procedures.
Exclusion Criteria:
- Evidence of an active ocular infection in either eye
- History or presence of ocular surface disorders not related to dry eye in either eye
- History or evidence of eyelid abnormality in either eye
- Use of topical cyclosporine, topical corticosteroids or any other topical medication for the treatment of dry eye in either eye within 30 days of study enrolment
- History of any ocular surgery (including laser or refractive surgical procedures) in either eye within the 90 days before study enrolment. Ocular surgery will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period
- Presence or history of any ocular or systemic disorder or condition that might significantly hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct of trail procedures (e.g. ocular trauma, progressive or degenerative corneal conditions, uveitis, systemic vasculitis, collagen vascular diseases, poorly controlled diabetes, autoimmune disease, systemic infection.)
- Known hypersensitivity to one of the components of the study or procedural medications
- Participation in another clinical study at the same time as the present study or within 90 days of baseline visit
- History of drug, medication or alcohol abuse or addiction.
Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
- are currently pregnant or,
- have a positive result on the urine pregnancy test at the Screening/Baseline Visit or,
- intend to become pregnant during the study treatment period or,
- are breast-feeding or,
- not willing to use highly effective birth control measures, such as: Hormonal contraceptives - oral, implanted, transdermal, or injected and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD during the entire course of and 30 days after the study treatment periods.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lubricin
Lubricin 150 µg/ml eye drops solution
|
Lubricin 150 µg/ml eye drops
|
Active Comparator: Sodium Hyaluronate
Sodium hyaluronate 0.13% eye drops
|
Sodium hyaluronate 0.13% eye drops
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SANDE
Time Frame: day 28±4
|
SANDE Questionnaire - TOTAL SCORE
|
day 28±4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular Total Tolerability Score
Time Frame: day 28±4
|
VAS
|
day 28±4
|
Oxford score
Time Frame: day 28±4
|
Corneal fluorescein surface staining
|
day 28±4
|
Tear Osmolarity
Time Frame: day 28±4
|
Tear osmolarity is an important indicator of the eye surface health.
<300 mOsm/L: normal; 300 < mOsm/L< 320: mild instability of the tear film; 320 < mOsm/L< 340: moderate; <340: severe.
|
day 28±4
|
Schirmer-I Test
Time Frame: day 28±4
|
Schirmer's test I (without anaesthesia)
|
day 28±4
|
Tear Film Break Up Time
Time Frame: day 28±4
|
TFBUT
|
day 28±4
|
Best corrected distance visual
Time Frame: day 28±4
|
BCVA
|
day 28±4
|
Corneal fluorescein surface staining (Oxford score)
Time Frame: day 28±4
|
The Oxford score divides corneal staining into six groups according to severity from 0 (absent) to 5 (severe).
The examiner compares the overall appearance of the patient's corneal staining with a reference figure, simulating the pattern of staining encountered in dry eye disease.
|
day 28±4
|
IOP
Time Frame: day 28±4
|
Intraocular pressure
|
day 28±4
|
TEAE
Time Frame: day 28±4
|
Adverse Events occurring after the first dose of Device
|
day 28±4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Caterina Gagliano, MD, Policlinico Vittorio Emanuele, Pres. Osp. G. Rodolico Clinica Oculistica
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Lacrimal Apparatus Diseases
- Keratoconjunctivitis
- Conjunctivitis
- Conjunctival Diseases
- Keratitis
- Corneal Diseases
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Xerophthalmia
- Physiological Effects of Drugs
- Immunologic Factors
- Protective Agents
- Adjuvants, Immunologic
- Viscosupplements
- Hyaluronic Acid
Other Study ID Numbers
- LUB0114MD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eye Syndrome
-
Olympic Ophthalmics, Inc.RecruitingMicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye SyndromeUnited States
-
Fidia Farmaceutici s.p.a.RecruitingDry Eye Syndrome (DES)Italy
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
Senju Pharmaceutical Co., Ltd.CompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
AllerganCompletedDry Eye Syndrome | Dry Eye DiseaseUnited States
-
Applied Science & Performance InstituteTrue Eye Experts - New Tampa; True Eye Experts - Lutz; True Eye Experts - South...CompletedDry Eye | Dry Eye SyndromesUnited States
-
ReGenTree, LLCCompletedDry Eye | Dry Eye SyndromesUnited States
-
LantibioRiver Plate Biotechnology, Inc.; Rx Development Resources, LLCCompletedSafety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye SyndromeDry Eye DiseaseUnited States
-
University of Alabama at BirminghamCompletedContact Lens Wearers With Dry Eye SyndromeUnited States
Clinical Trials on Lubricin
-
Aydin Adnan Menderes UniversityEnrolling by invitationInfective EndocarditisTurkey
-
Dompé Farmaceutici S.p.ACompleted
-
Dompé Farmaceutici S.p.ACompleted